

**EGFR CIRCULATING TUMOUR DNA (PLASMA) ANALYSIS REQUEST FORM**

Sarah Cannon Molecular Diagnostics  
 Ground Floor, Shropshire House  
 1 Capper Street, London WC1E 6JA

TEL: +44 (0)203 794 1920

EMAIL: [info@sarahcannon-md.co.uk](mailto:info@sarahcannon-md.co.uk)



Part of HCA Healthcare UK

Web: [www.sarahcannon-md.co.uk](http://www.sarahcannon-md.co.uk)

**NOTE: This test is primarily intended for use in non-small cell lung cancer patients who are progressing on EGFR TKI therapy. Blood must be drawn into the correct stabilisation tubes (Roche, Cell free DNA collection, REF:0778566601) and be shipped at ambient temperature for receipt by the laboratory within 96 hours of the draw time. Users who are unfamiliar with the process and/or the potential advantages & disadvantages of circulating tumour DNA based analysis are strongly advised to contact the laboratory for advice before proceeding.**

**FOR LABORATORY USE ONLY**

SCMD No:	Received by:	Received (Date/Time):
----------	--------------	-----------------------

**INDIVIDUAL AUTHORISING REQUEST (e.g. Clinician)**

Name:	Address:
Phone:	

**DESTINATION FOR ANALYSIS REPORT (ESSENTIAL – Results may be delayed if not completed)**

Name:	Address:
Phone:	
Note: If as above please tick here <input type="checkbox"/>	

Required Method(s) for Report Delivery (please tick all that apply):    Post     Fax     Email

Results Fax number(s):	Results e-mail(s):
------------------------	--------------------

**INVOICING DETAILS (ESSENTIAL – Results may be delayed if not completed in full)**

Contact name:	Full Organisation Name and Postal Address:
Phone:	
Email:	
Note: An authorisation code is mandatory if providing private medical insurance details	

**PATIENT DETAILS (At least 3 unique identifiers are mandatory)**

Surname:	Forename:	DOB (DD/MM/YY):	Gender: M <input type="checkbox"/> F <input type="checkbox"/>
Hospital/Laboratory Name:	Hospital/Laboratory case number:	Requester Ref (if applicable):	

**CLINICAL / SAMPLE DETAILS (Please provide as much information as possible)**

Current EGFR TKI therapy (e.g. gefitinib):	Original Sensitising variant (e.g. L858R or exon 19 del):
Date & Time of blood draw (Mandatory*):	Total number of Roche cfDNA tubes supplied:
*Specimens may be rejected if the time from draw to processing is not verifiable.    Note: One tube is sufficient if above the 'minimum fill' level indicator.	

**Any other comments or relevant clinical information:**